Valerie Vanhooren, PhD

Valerie is co-founder and CEO of Ona Therapeutics. Since 2019 she has guided the growth and development of Ona’s pipeline of first-in-class in ADCs and antibodies and secured over 35 million euros from a syndicate of international investors and non-dilutive grants. She has extensive experience in discovery and development of antibodies and protein conjugates for oncology. Prior to Ona she held leading R&D roles at SpliceBio and Ablynx (acquired by Sanofi), where she led drug development collaborative partnerships with multiple internationally operating pharmaceutical entities, including Merck and AbbVie. Valerie holds a PhD in Biotechnology from the University of Ghent, Belgium.